Name |
Position |
Country |
Term |
Time in Office |
A. St John |
Chair |
AU |
2nd |
2021 01 - 2023 12 |
R. Christenson |
Member |
US | 2nd |
2021 01 - 2023 12 |
M.O'Kane |
Member |
UK | 2nd |
2021 01 - 2023 12 |
P.Jüelicher |
Member |
DE | 2nd |
2021 01 - 2023 12 |
F.Curcio | WASPaLM Rep. |
IT |
||
M.Oellerich | WASPaLM Rep. |
DE |
||
I.Parwati | WASPaLM Rep. |
ID |
||
N.Massakazu Sumita | WASPaLM Rep. |
BR |
||
R.Verna | WASPaLM Rep. |
IT |
||
C. Price | Consultant |
UK |
1. To advocate adoption of the value proposition in laboratory medicine/healthcare
Continuing work in the form of peer-reviewed publications, congress symposia and presentations to local meetings is required to describe and define the value proposition in laboratory medicine and to advocate its widespread adoption. During the first 3 years of this committee it is intended that this work would be restricted to laboratory medicine professionals albeit with interaction with appropriate clinical specialists relevant to the particular tests As the group expands the body of knowledge on the value proposition in firstly laboratory medicine and then in other healthcare disciplines then this work can be extended.
2. To develop a compendium of tools for laboratory medicine specialists to establish the value for individual medical tests within individual health care systems.
Case studies will be undertaken for specific medical tests according to the principles of the value proposition in specific healthcare systems. There is a need to develop the principles for the preparation of such case studies for publication in the current peer-reviewed journals in order that they reach the appropriate audience. This work has been commenced and will continue for 3 years. It will include test laboratories applying the value proposition framework to a particular medical test and assessing the outcomes. At the end of this period it is proposed that a compendium of tools generalisable for the preparation of documents demonstrating the value proposition for any medical test will be described in a major review publication.
Name |
National Society |
Country |
F.B. Aksungar |
Turkish Biochemical Society | TR |
T. Badrick | Australasian Association for Clinical Biochemistry and Laboratory Medicine (AACB) | AU |
M. Barrionuevo Gonzalez | Sociedad Española de Medicina de Laboratorio | ES |
P. Laitinen | Finnish Society of Clinical Chemistry | FI |
K. Saito | Japan Society of Clinical Chemistry | JP |
D.Grenache | American Association Clinical Chemistry | US |
Name |
Company |
|
B. Meyer |
BD LIFE SCIENCES |
|
B. Milojkovic | NOVA BIOMEDICAL | |
J. Nørgaard Andreasen | RADIOMETER |
Dr. Andrew St.John
ARC Consulting
14 Learoyd Street
MT Lawley, WA, 6050
Australia
email: astjohn14@gmail.com